Addressing the limitations of other gene delivery platform technologies.
Recent breakthroughs in gene therapy save lives, but there's still a long way to go. EVADER™, Chameleon's next generation, AAV based technology is the next generation gene therapy.
Minimal Immune Response
Current treatments fail when the patient’s immune system attacks the gene therapy.
With reduced immune response from initial treatment, additional doses may be given to potentially boost immediate response or maintain longer term disease correction.
Evading attack by the immune system, each dose may be more effective.
Every child with a genetic disorder deserves a safe and effective treatment.
MILLION CHILDREN PER YEAR
born with serious genetic disorders*
*March of Dimes Report: https://www.marchofdimes.org/mission/march-of-dimes-global-report-on-birth-defects.aspx accessed on April 21, 2021
Current gene therapies offer hope but have limitations:
OF INFANT FATALITIES
born with serious genetic disorders
CHILDREN ARE OFTEN EXCLUDED
from gene therapy
can't be treated
Severe Hemophilia A
Severe Hemophilia B
Duchenne Muscular Dystrophy
Limb Girdle Muscular Dystrophy
Central Nervous System Disorders
Lysosomal Storage Disorders
Niemann-Pick Type C (“Childhood Alzheimers”)
Meeting significant unmet needs.
Our platform technology has broad applicability across types of disorders. We anticipate that our treatment could effectively address these types of conditions within the next five years.